Accessibility Menu
 
Bolt Biotherapeutics logo

Bolt Biotherapeutics

(NASDAQ) BOLT

Current Price$4.65
Market Cap$9.15M
Since IPO (2021)-99%
5 Year-99%
1 Year-46%
1 Month+2%

Bolt Biotherapeutics Financials at a Glance

Market Cap

$9.15M

Revenue (TTM)

$7.70M

Net Income (TTM)

$33.38M

EPS (TTM)

$-17.78

P/E Ratio

-0.27

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$4.65

Volume

33,736

Open

$4.60

Previous Close

$4.76

Daily Range

$4.53 - $4.88

52-Week Range

$3.91 - $9.66

BOLT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bolt Biotherapeutics

Industry

Biotechnology

Employees

23

CEO

William P. Quinn, MBA

Headquarters

Redwood City, CA 94063, US

BOLT Financials

Key Financial Metrics (TTM)

Gross Margin

81%

Operating Margin

-5%

Net Income Margin

-4%

Return on Equity

-80%

Return on Capital

-72%

Return on Assets

-59%

Earnings Yield

-3.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.15M

Shares Outstanding

1.92M

Volume

33.74K

Short Interest

0.00%

Avg. Volume

27.43K

Financials (TTM)

Gross Profit

$6.20M

Operating Income

$34.63M

EBITDA

$33.14M

Operating Cash Flow

$39.85M

Capital Expenditure

$72.00K

Free Cash Flow

$39.92M

Cash & ST Invst.

$27.50M

Total Debt

$22.96M

Bolt Biotherapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.50M

N/A

Gross Profit

$1.30M

+404.9%

Gross Margin

51.96%

N/A

Market Cap

$9.15M

N/A

Market Cap/Employee

$175.90K

N/A

Employees

52

N/A

Net Income

$6.63M

+58.4%

EBITDA

$5.35M

+65.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$4.55M

-79.4%

Accounts Receivable

$973.00K

-16.5%

Inventory

$0.00

N/A

Long Term Debt

$20.13M

-12.3%

Short Term Debt

$2.83M

+25.5%

Return on Assets

-58.81%

N/A

Return on Invested Capital

-71.68%

N/A

Free Cash Flow

$7.16M

+50.4%

Operating Cash Flow

$7.16M

+50.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INABIN8bio, Inc.
$2.00+16.28%
RNAZTransCode Therapeutics, Inc.
$8.98-3.54%
CLRBCellectar Biosciences, Inc.
$3.24+1.89%
EVGNEvogene Ltd.
$0.85-0.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
RITMRithm Capital
$8.77-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%
INFYInfosys
$13.12+0.01%

Questions About BOLT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.